Medical Policy Updates

Notification of Policy Revisions Effective October 25, 2011 (Posted July 19, 2011)

Medical Policy	Revision
Tyrosine Kinase Mutations in Myeloproliferative Neoplasms	New policy. "JAK2 tyrosine kinase and MPL mutation testing may be considered medically necessary in the diagnosis of patients presenting with clinical, laboratory, or pathological findings suggesting classic forms of myeloproliferative neoplasms (MPN), that is, polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis (PMF). JAK2 tyrosine kinase and MPL mutation testing may be considered investigational in all other circumstances" Notification given July 19, 2011. Policy implemented October 25, 2011.

Medical Policy

Revision

Tyrosine Kinase Mutations in Myeloproliferative Neoplasms

New policy. "JAK2 tyrosine kinase and MPL mutation testing may be considered medically necessary in the diagnosis of patients presenting with clinical, laboratory, or pathological findings suggesting classic forms of myeloproliferative neoplasms (MPN), that is, polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis (PMF). JAK2 tyrosine kinase and MPL mutation testing may be considered investigational in all other circumstances" Notification given July 19, 2011. Policy implemented October 25, 2011.